Entera Bio Ltd. Ordinary Shares - ENTX STOCK NEWS

Entera Bio Ltd. (NASDAQ: ENTX) announced the publication of its Phase 2a study results for EB612 in the Journal of Bone and Mineral Research. The study demonstrated a 42% reduction in calcium supplement use (p=0.001) among patients with hypoparathyroidism. Significant improvements included maintenance of serum calcium levels, a 23% decrease in serum phosphate (p=0.0003), and a 5% increase in quality of life scores (p=0.03). The trial involved 19 patients, with 17 completing it without serious adverse events. Entera plans to enhance EB612 formulations and start a new trial in 2022.

Entera Bio Ltd. (NASDAQ: ENTX) has initiated a research program to develop an oral GLP-2 analog using its proprietary platform technology. This move aims to provide an alternative to the current injectable treatment for short bowel syndrome, teduglutide, which generated $574 million in sales in 2019. The company believes GLP-2 analogs could address various metabolic diseases, enhancing patient compliance and reducing costs. Entera's technology has significant potential in the oral delivery of large molecules, aligning with a growing market for biologics valued at $20 billion annually.

Entera Bio Ltd. (NASDAQ: ENTX) announced a Letter to Shareholders from newly appointed CEO Spiros Jamas, emphasizing the company's progress in developing orally delivered therapeutics. They bolstered their balance sheet with $8.6 million in cash, funding clinical programs into Q3 2021. Key highlights include FDA approval for their oral osteoporosis drug, EB613, and positive interim data from clinical trials. The potential market for EB613 is projected to grow to $20 billion if successful. The company also reported positive results for EB612, an oral treatment for hypoparathyroidism, meeting all trial endpoints.

Entera Bio Ltd. (NASDAQ: ENTX) has received FDA approval to proceed with the initial U.S. clinical trial for EB613, an orally delivered human parathyroid hormone (1-34) aimed at treating osteoporosis. This positions EB613 as a pioneering once-daily oral treatment for osteoporosis patients. The ongoing Phase 2 trial's biomarker data is expected in Q1 2021, with final bone mineral density results anticipated in Q2 2021. The company aims for a pivotal Phase 3 trial post-analysis, highlighting the unmet need for oral PTH therapies.

Entera Bio Ltd. (NASDAQ: ENTX) has appointed Spiros Jamas as its new CEO effective January 4, 2021, succeeding interim CEO Dr. Roger Garceau. Dr. Jamas brings over 30 years of biopharmaceutical experience, aiming to advance Entera’s osteoporosis treatment EB613 and hypoparathyroidism treatment EB612, both in Phase 2 trials. The company anticipates key data readouts in the first half of 2021, presenting potential growth opportunities. Shareholder approval is required for Dr. Jamas' engagement terms.

Entera Bio Ltd. (NASDAQ: ENTX) announced the completion of enrollment in its Phase 2 clinical trial of EB613, aimed at treating osteoporosis. A total of 161 subjects were randomized, with interim data showing a 2.15% mean increase in lumbar spine bone mineral density (BMD) compared to placebo. The company plans to report additional biomarker data in Q1 and Q2 of 2021. Financially, Entera reported revenues of $144,000 for the nine months ended September 30, 2020, alongside an operating loss of $(8.8) million and a net loss of $(7.7) million. Cash reserves stood at $7.1 million as of September 30, 2020.

Entera Bio Ltd. (NASDAQ: ENTX) will release its business and financial results for Q3 2020 on November 19, 2020, before U.S. markets open. The management team will host a conference call at 8:30 a.m. ET on that day to discuss the results, with a Q&A session to follow. Participants can join the call by dialing (855) 547-3865 within the U.S. or (409) 217-8787 internationally, using the conference ID 9495026. A live audio webcast will also be available on Entera's website.

Entera Bio Ltd. (NASDAQ: ENTX) announced the completion of enrollment in its Phase 2 clinical trial for EB613, an oral treatment for osteoporosis. This study involves 161 postmenopausal women and aims to evaluate the drug's effect on bone mineral density (BMD). Interim results showed a placebo-adjusted BMD increase of 2.15% in the highest dose group. Full biomarker data is expected in Q1 2021, with final results due in Q2 2021. Entera has $7.1 million in cash, sufficient to support operations into the second quarter of 2021, despite challenges from COVID-19.

Entera Bio Ltd. (NASDAQ: ENTX) announced a virtual presentation at the H.C. Wainwright Annual Israel Conference on November 12, 2020 at 8:00 a.m. ET. The event will showcase its advancements in orally delivered large molecule therapeutics, targeting unmet medical needs in healthcare.

Entera’s proprietary technology addresses challenges in drug absorption, focusing on its lead candidates, EB613 for osteoporosis and EB612 for hypoparathyroidism, currently in Phase 2 clinical development.